M&A / Deals

Latus Bio secures $97m in funding to boost gene therapy access

Pharmaceutical Business Review

The financing includes a $43m extension led by 8VC, with participation from existing investors BioAdvance, Benjamin Franklin Technology Partners, DCVC Bio, Gaingels, Hatch BioFund and Modi Ventures.

Gene Therapy Platform

Read full story

pharminent May 5, 2026 (Last updated: May 5, 2026)

Pharmaceutical Business Review

The financing includes a $43m extension led by 8VC, with participation from existing investors BioAdvance, Benjamin Franklin Technology Partners, DCVC Bio, Gaingels, Hatch BioFund and Modi Ventures.

Gene Therapy Platform

Read full story

Related Stories

UCB doubles down on TCEs with $2.2bn Candid buyout

Autoimmune disease biotech Odyssey sets terms for $225m IPO

Cytospire hauls in $83M for a new type of T cell engager

You May Have Missed

QurAlis’ Phase 2 data bolster case for genetic approach to sporadic ALS

Pfizer stays the course for 2026 guidance, dulling impact of Q1 earnings beat

Cytokinetics heart drug scores in closely watched trial

Specialty Pharmacy Accreditation: DCI’s Exclusive Analysis Reveals a Market at an Inflection Point